Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 77.63 GBp
Change Today -0.50 / -0.64%
Volume 4.3M
VER On Other Exchanges
As of 11:35 AM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

vernalis plc (VER) Snapshot

76.75 GBp
Previous Close
78.13 GBp
Day High
77.63 GBp
Day Low
76.75 GBp
52 Week High
09/10/15 - 87.25 GBp
52 Week Low
04/17/15 - 44.50 GBp
Market Cap
Average Volume 10 Days
-0.0060 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VERNALIS PLC (VER)

Related News

No related news articles were found.

vernalis plc (VER) Related Businessweek News

No Related Businessweek News Found

vernalis plc (VER) Details

Vernalis plc, a research and development stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Frovatriptan, a selective 5-HT1B/1D receptor agonist for an acute oral treatment of migraine headache and its associated symptoms. The company also has a development and licensing agreement to develop approximately six extended-release liquid formulations of short-acting prescription cough cold products. In addition, it is developing V158866, a fatty acid amide hydrolase inhibitor that is in Phase II proof-of-concept (POC) clinical trial for the treatment of various pain and other CNS disorders; and V81444, an adenosine A2A receptor antagonist, which is in Phase Ib/II POC clinical trial for the treatment of Parkinson’s disease and other neurological disorders. Further, the company is developing AUY922, an intravenous Hsp90 inhibitor for treating a range of cancers in Phase I and Phase II clinical trial; CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukaemia and myelodysplastic syndrome under Phase II trial; V158411 molecule and Servier 1, which are in pre-clinical stage for treating cancer; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc; Genentech Inc; H. Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc; Novartis Pharma AG; Servier Research Group; Taisho Pharmaceutical Co., Ltd.; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.

91 Employees
Last Reported Date: 09/29/15
Founded in 1988

vernalis plc (VER) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 991.0K GBP
Chief Financial Officer and Director
Total Annual Compensation: 676.0K GBP
Compensation as of Fiscal Year 2015.

vernalis plc (VER) Key Developments

Vernalis plc Announces Audited Consolidated Earnings Results for the Eighteen Month Period Ended June 30, 2015

Vernalis plc announced audited consolidated earnings results for the eighteen month period ended June 30, 2015. For the period, revenue was GBP 19,882,000. Operating loss was GBP 11,835,000. Loss on ordinary activities before taxation was GBP 9,259,000. Loss for the period was GBP 6,401,000 or 1.4 pence per basic and diluted share. Net cash used in operating activities were GBP 10,336,000. Purchase of property, plant and equipment was GBP 1,005,000. Purchase of intangible fixed assets GBP 7,474,000.

Vernalis plc and Tris Pharma Announce Availability of Cough Relief Syrup in US

Vernalis plc and Tris Pharma announced the availability of Tuzistra XR, an extended-release oral suspension, CIII, indicated for cough relief, in the US. Tuzistra XR, was approved by the FDA on April 30, 2015. It is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. Tuzistra XR is the only codeine-based extended-release cough cold syrup available to patients and physicians in the US. Tuzistra XR was developed using Tris Pharma's liquid sustained release technology, LiquiXR, which allows for extended drug delivery throughout a 12-hour dosing period.

Vernalis plc to Report 18 Months Period Ending Jun 30, 2015 Results on Sep 29, 2015

Vernalis plc announced that they will report 18 months, period ending Jun 30, 2015 results at 7:00 AM, GMT Standard Time on Sep 29, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VER:LN 77.63 GBp -0.50

VER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.120.90 CHF +0.60
Endo International PLC $67.28 USD -3.78
Mylan NV $43.90 USD +0.24
Medicines Co/The $38.29 USD -0.73
UCB SA €72.31 EUR +1.74
View Industry Companies

Industry Analysis


Industry Average

Valuation VER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERNALIS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at